FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217720899> ?p ?o ?g. }

• W3217720899 endingPage "1063" @default.
• W3217720899 startingPage "1047" @default.
• W3217720899 abstract "Neoadjuvant treatment (NT) with chemotherapy (Ch) is a standard option for resectable stage III (N2) NSCLC. Several studies have suggested benefits with the addition of radiotherapy (RT) to NT Ch. The International Association for the Study of Lung Cancer (IASLC) published recommendations for the pathological response (PHR) of NSCLC resection specimens after NT.To contribute to the IASLC recommendations showing our results of PHR to NT Ch vs NT chemoradiotherapy (ChRT).We analyzed 67 consecutive patients with resectable stage III NSCLC with positive mediastinal nodes treated with surgery after NT Ch or NT ChRT between 2013 and 2020. After NT, all patients were evaluated for radiological response (RR) according to Response Evaluation Criteria in Solid Tumours criteria and evaluated for surgery by a specialized group of thoracic surgeons. All histological samples were examined by the same two pathologists. PHR was evaluated by the percentage of viable cells in the tumor and the resected lymph nodes.Forty patients underwent NT ChRT and 27 NT Ch. Fifty-six (83.6%) patients underwent surgery (35 ChRT and 21 Ch). The median time from ChRT to surgery was 6 wk (3-19) and 8 wk (3-21) for Ch patients. We observed significant differences in RR, with disease progression in 2.5% and 14.8% of patients with ChRT and Ch, respectively, and partial response in 62.5% ChRT vs 29.6% Ch (P = 0.025). In PHR we observed ≤ 10% viable cells in the tumor in 19 (54.4%) and 2 cases (9.5%), and in the resected lymph nodes (RLN) 30 (85.7%) and 7 (33.3%) in ChRT and Ch, respectively (P = 0.001). Downstaging was greater in the ChRT compared to the Ch group (80% vs 33.3%; P = 0.002). In the univariate analysis, NT ChRT had a significant impact on partial RR [odds ratio (OR) 12.5; 95% confidence interval (CI): 1.21 - 128.61; P = 0.034], a decreased risk of persistence of cancer cells in the tumor and RLN and an 87.5% increased probability for achieving downstaging (OR 8; 95%CI: 2.34-27.32; P = 0.001).We found significant benefits in RR and PHR by adding RT to Ch as NT. A longer follow-up is necessary to assess the impact on clinical outcomes." @default.
• W3217720899 created "2021-12-06" @default.
• W3217720899 creator A5006049798 @default.
• W3217720899 creator A5008115364 @default.
• W3217720899 creator A5015433801 @default.
• W3217720899 creator A5018931713 @default.
• W3217720899 creator A5023258780 @default.
• W3217720899 creator A5026703442 @default.
• W3217720899 creator A5035744703 @default.
• W3217720899 creator A5036469551 @default.
• W3217720899 creator A5041509163 @default.
• W3217720899 creator A5043771067 @default.
• W3217720899 creator A5044063978 @default.
• W3217720899 creator A5044141782 @default.
• W3217720899 creator A5054856779 @default.
• W3217720899 creator A5057268783 @default.
• W3217720899 creator A5061320700 @default.
• W3217720899 creator A5067673746 @default.
• W3217720899 creator A5077239467 @default.
• W3217720899 creator A5089070091 @default.
• W3217720899 date "2021-11-24" @default.
• W3217720899 modified "2023-10-16" @default.
• W3217720899 title "Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC. Contribution of IASLC recommendations" @default.
• W3217720899 cites W1481153401 @default.
• W3217720899 cites W1842558207 @default.
• W3217720899 cites W1870429510 @default.
• W3217720899 cites W1968819130 @default.
• W3217720899 cites W1988160404 @default.
• W3217720899 cites W2008698822 @default.
• W3217720899 cites W2013968289 @default.
• W3217720899 cites W2036067943 @default.
• W3217720899 cites W2048316728 @default.
• W3217720899 cites W2077910495 @default.
• W3217720899 cites W2085275548 @default.
• W3217720899 cites W2104134194 @default.
• W3217720899 cites W2104701073 @default.
• W3217720899 cites W2110996227 @default.
• W3217720899 cites W2128147114 @default.
• W3217720899 cites W2133223019 @default.
• W3217720899 cites W2134291074 @default.
• W3217720899 cites W2159395831 @default.
• W3217720899 cites W2171462712 @default.
• W3217720899 cites W2182482244 @default.
• W3217720899 cites W2527748695 @default.
• W3217720899 cites W2590592584 @default.
• W3217720899 cites W2603948731 @default.
• W3217720899 cites W2624942935 @default.
• W3217720899 cites W2783689974 @default.
• W3217720899 cites W2801343741 @default.
• W3217720899 cites W2893824814 @default.
• W3217720899 cites W2897193647 @default.
• W3217720899 cites W2951872058 @default.
• W3217720899 cites W2991807637 @default.
• W3217720899 cites W3003197494 @default.
• W3217720899 cites W3089266118 @default.
• W3217720899 cites W3119946561 @default.
• W3217720899 cites W4251929212 @default.
• W3217720899 cites W4383858999 @default.
• W3217720899 cites W811799089 @default.
• W3217720899 doi "https://doi.org/10.5306/wjco.v12.i11.1047" @default.
• W3217720899 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34909399" @default.
• W3217720899 hasPublicationYear "2021" @default.
• W3217720899 type Work @default.
• W3217720899 sameAs 3217720899 @default.
• W3217720899 citedByCount "1" @default.
• W3217720899 countsByYear W32177208992022 @default.
• W3217720899 crossrefType "journal-article" @default.
• W3217720899 hasAuthorship W3217720899A5006049798 @default.
• W3217720899 hasAuthorship W3217720899A5008115364 @default.
• W3217720899 hasAuthorship W3217720899A5015433801 @default.
• W3217720899 hasAuthorship W3217720899A5018931713 @default.
• W3217720899 hasAuthorship W3217720899A5023258780 @default.
• W3217720899 hasAuthorship W3217720899A5026703442 @default.
• W3217720899 hasAuthorship W3217720899A5035744703 @default.
• W3217720899 hasAuthorship W3217720899A5036469551 @default.
• W3217720899 hasAuthorship W3217720899A5041509163 @default.
• W3217720899 hasAuthorship W3217720899A5043771067 @default.
• W3217720899 hasAuthorship W3217720899A5044063978 @default.
• W3217720899 hasAuthorship W3217720899A5044141782 @default.
• W3217720899 hasAuthorship W3217720899A5054856779 @default.
• W3217720899 hasAuthorship W3217720899A5057268783 @default.
• W3217720899 hasAuthorship W3217720899A5061320700 @default.
• W3217720899 hasAuthorship W3217720899A5067673746 @default.
• W3217720899 hasAuthorship W3217720899A5077239467 @default.
• W3217720899 hasAuthorship W3217720899A5089070091 @default.
• W3217720899 hasBestOaLocation W32177208991 @default.
• W3217720899 hasConcept C121608353 @default.
• W3217720899 hasConcept C126322002 @default.
• W3217720899 hasConcept C141071460 @default.
• W3217720899 hasConcept C142724271 @default.
• W3217720899 hasConcept C143998085 @default.
• W3217720899 hasConcept C146357865 @default.
• W3217720899 hasConcept C151730666 @default.
• W3217720899 hasConcept C207886595 @default.
• W3217720899 hasConcept C2776256026 @default.
• W3217720899 hasConcept C2776694085 @default.
• W3217720899 hasConcept C2778292576 @default.
• W3217720899 hasConcept C2778424827 @default.

• next